BioStock: Xintela reports promising results in Covid-19 project

During the autumn, Xintela has investigated whether the company’s selected stem cells, XSTEM, can be used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung complication that affects some Covid-19 patients. The company has completed the majority of the preclinical study, and so far, it has given promising results. They have seen a clear improvement in lung function after the XSTEM treatment and a reversal of the critical ARDS condition – something that is very difficult to achieve with current treatments.

Read the full article at biostock.se:

https://www.biostock.se/en/xintela-reports-promising-results-in-covid-19-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se